(CercleFinance.com) – The group announces that the FDA has approved Xolair as the first and only drug intended for children and adults suffering from one or more food allergies.
The approval is based on data from the NIH-sponsored phase III OUTMATCH study, which showed that a significantly higher proportion of food allergy patients as young as one year of age treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew nuts without allergic reaction. compared to placebo
More than 40% of children and more than half of adults with food allergies have had a severe reaction at least once 1.2.
Detailed results from OUTMATCH will be presented in a late-breaking symposium at the 2024 AAAI Annual Meeting.
‘Xolair offers patients and their families an important new treatment option that can help redefine how food allergies are managed and reduce the often serious allergic reactions that can result from exposure to food allergens,’ said Levi Garraway, MD, Ph.D., Chief Medical Officer of Roche.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
